Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: there is no need for a vaccine program in older adults at present.

Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: there is no need for a vaccine program in older adults at present.

Bibliographic Details
Main Authors:	Trück, J, Lazarus, R, Jonsdottir, I, Klugman, K, Pollard, A
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Herd protection induced by pneumococcal conjugate vaccine
by: Keith P Klugman
Published: (2014-07-01)

Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients
by: Thijs W. Hoffman, MD, et al.
Published: (2020-06-01)

Differences in immunization site pain in toddlers vaccinated with either the 10- or the 13-valent pneumococcal conjugate vaccine
by: Trück, J, et al.
Published: (2018)

A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults.
by: Lazarus, R, et al.
Published: (2011)

Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule
by: Trück, J, et al.
Published: (2016)

Pneumococcal vaccination in persons living with HIV: Pneumococcal conjugate, polysaccharide or both?
by: Bhavna Dhingra, et al.
Published: (2020-12-01)

Polysaccharide responsiveness is not biased by prior pneumococcal-conjugate vaccination.
by: Jens Magnus Bernth-Jensen, et al.
Published: (2013-01-01)

No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine
by: Licciardi, P, et al.
Published: (2016)

Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants
by: Hua Zhou, et al.
Published: (2018-06-01)

Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells.
by: Clutterbuck, E, et al.
Published: (2012)

Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
by: Mitchell, R, et al.
Published: (2013)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019-03-01)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
by: Miguel Gouveia, et al.
Published: (2019-04-01)

Conjugate pneumococcal vaccines: Need and choice in India
by: Akash Malik, et al.
Published: (2013-01-01)

Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain
by: I. Rivero-Calle, et al.
Published: (2020-06-01)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023-06-01)

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
by: Trück, J, et al.
Published: (2016)

Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
by: Grant A. Mackenzie, et al.
Published: (2022-01-01)

Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.
by: Anita H J van den Biggelaar, et al.
Published: (2017-01-01)

Efficacy of conjugate vaccines in pneumococcal infection prevention
by: A. L. Perova, et al.
Published: (2014-09-01)

The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses.
by: O'Connor, D, et al.
Published: (2014)

Invasive Pneumococcal Disease after Routine Pneumococcal Conjugate Vaccination in Children, England and Wales
by: Shamez N. Ladhani, et al.
Published: (2013-01-01)

Meningococcal polysaccharide-protein conjugate vaccines.
by: Snape, MD, et al.
Published: (2005)

B cell response to pneumococcal vaccines
by: Trück, J
Published: (2014)

Safety of simultaneous vaccination of 13-valent pneumococcal polysaccharide conjugate vaccine with other vaccines in Shanghai from 2017 to 2021
by: YANG Shoufei, et al.
Published: (2022-08-01)

Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine
by: Matt Wasserman, et al.
Published: (2018-01-01)

Preventive Efficacy of Pneumococcal Conjugated Vaccine (Population Aspects)
by: I. N. Protasova, et al.
Published: (2022-01-01)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
by: Hyunju Lee, et al.
Published: (2014-02-01)

Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study: statistical analysis plan
by: Grant A. Mackenzie, et al.
Published: (2024-03-01)

Multiplexed suspension array immunoassays for detection of antibodies to pneumococcal polysaccharide and conjugate vaccines
by: Sherry A. Dunbar
Published: (2023-11-01)

Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine
by: James Z. Deng, et al.
Published: (2023-01-01)

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
by: Allison E.B. Turner, et al.
Published: (2017-03-01)

Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants
by: von Kries Rüdiger, et al.
Published: (2010-01-01)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
by: Sabine Haggenburg, et al.
Published: (2023-07-01)

Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia
by: Vesa Lindström, et al.
Published: (2019-12-01)

Impact of Pneumococcal Conjugate Vaccination of Infants on Pneumonia and Influenza Hospitalization and Mortality in All Age Groups in the United States
by: Lone Simonsen, et al.
Published: (2011-03-01)

Parental views on the introduction of an infant pneumococcal vaccine.
by: Chantler, T, et al.
Published: (2006)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
by: Min-Joo Choi, et al.
Published: (2018-08-01)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019-03-01)